<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Weekly Coronavirus Update - Medium]]></title>
        <description><![CDATA[Weekly wrap-up of the latest Coronavirus research and news for those who want a one-stop shop for peer-reviewed research findings written in a way that is easy to understand. - Medium]]></description>
        <link>https://medium.com/weekly-coronavirus-update?source=rss----7d3227ef66e6---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>Weekly Coronavirus Update - Medium</title>
            <link>https://medium.com/weekly-coronavirus-update?source=rss----7d3227ef66e6---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 04:03:01 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/weekly-coronavirus-update" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, January 18, 2022]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-january-18-2022-6b61010120d6?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/6b61010120d6</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[coronavirus-update]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 18 Jan 2022 22:59:18 GMT</pubDate>
            <atom:updated>2022-01-18T22:59:18.126Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. I’m coming to you with a bit of a mini-update this week, as I’ve not had much time to read and summarize Covid research this week. This will be my last update for a while, as my work is back to being insanely busy. Aside from one much-needed mini-vacation, I’m going to be spending the majority of my nights and weekends doing work until at least March. I’ll be back to these updates when I can! If you want to be notified when I’m writing again, please be sure to subscribe to receive updates from this page via email. Until then, here’s the latest in Covid research:</p><p>1) Different nations have taken different approaches to prioritizing vaccinations in people with asthma. A peer-reviewed study published in The Lancet Respiratory Medicine sought to understand whether adults with asthma were at increased risk of severe Covid-19. The study analyzed data from people in Scotland, of whom over 4 million had been diagnosed with asthma. Amongst those, 7% had a confirmed case of Covid-19 between March 2020 and July 2021. Of those, 12.3% were admitted to hospital due to Covid. The study found that adults with asthma were at an increased risk of hospitalization due to Covid, and those who had required two or more courses of oral corticosteroids or had been admitted to hospital due to asthma at some stage were also at greater risk of ICU admission and death. The authors concluded that “patients with a recent asthma attack should be considered a priority group for booster COVID-19 vaccines.” You can read the full study here: <a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00543-9/fulltext">https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00543-9/fulltext</a></p><p>2) Research published in the CDC’s Morbidity and Mortality Weekly Report (MMWR) examined whether the Pfizer vaccine provided protection against multisystem inflammatory syndrome in children (MIS-C), a disease that can occur between 2–6 weeks after a Covid infection. Using data from 102 MIS-C patients and 181 hospitalized controls (children without MIS-C), the estimated effectiveness of two doses of the Pfizer vaccine in children aged 12–18 against MIS-C was 91%. Of the 102 MIS-C patients, 95% were not vaccinated. A total of 38 MIS-C patients required life support, none of whom were vaccinated. The researchers concluded, “Receipt of 2 doses of Pfizer-BioNTech vaccine is highly effective in preventing MIS-C in persons aged 12–18 years. These findings further reinforce the COVID-19 vaccination recommendation for eligible children.” You can read the full study here: <a href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7102e1.htm?s_cid=mm7102e1_w">https://www.cdc.gov/mmwr/volumes/71/wr/mm7102e1.htm?s_cid=mm7102e1_w</a></p><p>3) Researchers in Canada studied the functional mobility of adults aged 50 or over after having Covid-19. The study involved 24,114 people who were over 50 and lived in a community and found that these individuals had a two-fold increase in their odds of worsening mobility (such as their ability to engage in household activities) and physical function (such as standing up after sitting in a chair) after Covid-19 than those who never had the virus. The majority of participants (94.2%) in the study had mild-to-moderate cases of Covid and were never hospitalized. The authors concluded, “This cohort study among older adults in Canada found that receiving a COVID-19 diagnosis was significantly associated with worse mobility and functioning outcomes even in the absence of hospitalization. These findings suggest that interventions may be needed for individuals with mild to moderate COVID-19 who do not require hospitalization.” This study was peer-reviewed and published in the journal JAMA Network Open. You can read the full text here: <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787975">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787975</a></p><p>4) Now for a quick world update. In the US, the latest daily number of cases reported was 712,051 yesterday, although this contains data anomalies since many states did not report data on the Martin Luther King, Jr. Day holiday. The two-week average number of daily new cases is 790,553, which is a 62% increase over the past two weeks. Hospitalizations have increased 54% over the past two weeks and deaths have also increased 54% over this time period. Per capita, the states with the highest rates of infection include Rhode Island, Wisconsin, Vermont, Delaware, and Utah. In the entire population of the US, 63% of people are fully vaccinated. Amongst age 12 and up, the number is 72%. Of those age 65+, the number is 88%. The Biden administration’s government website for free rapid tests has gone live, and you can access it here: <a href="https://www.covidtests.gov/">https://www.covidtests.gov/</a> <br> — In the UK the daily number of new cases today was 94,432. Over the past two weeks there has been a 43% decrease in new cases but a 107% increase in deaths. Today there were 468 deaths, the highest number in 11 months. There are currently 19,450 people in hospital, which is 468 less than this time last week. Today Reuters News Agency reported that they saw a document stating that rapid tests would no longer be offered for free in the UK as of June 2022.<br> — Elsewhere, France set a new record today for its daily number of infections at 464,769. Italy also recorded a very high number of cases today with 228,179. Australia recorded its deadliest day of the pandemic with 74 deaths. The CDC in the US has warned against travel to Australia, as has the European Union. <br>Sources:<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br>UK numbers: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a> <br>UK rapid test info: <a href="https://www.reuters.com/world/uk/exclusive-britain-preparing-end-june-switch-paid-covid-tests-document-2022-01-18/">https://www.reuters.com/world/uk/exclusive-britain-preparing-end-june-switch-paid-covid-tests-document-2022-01-18/</a> <br>World updates: <a href="https://www.theguardian.com/world/live/2022/jan/18/coronavirus-news-live-poland-enters-fifth-covid-wave-australia-reports-record-daily-death-toll?filterKeyEvents=false&amp;page=with:block-61e70a728f08d4a2252dc44d#block-61e70a728f08d4a2252dc44d">https://www.theguardian.com/world/live/2022/jan/18/coronavirus-news-live-poland-enters-fifth-covid-wave-australia-reports-record-daily-death-toll?filterKeyEvents=false&amp;page=with:block-61e70a728f08d4a2252dc44d#block-61e70a728f08d4a2252dc44d</a><br>Australia deaths: <a href="https://www.independent.co.uk/news/health/covid-restrictions-omicron-cases-news-live-b1995038.html#post-542079">https://www.independent.co.uk/news/health/covid-restrictions-omicron-cases-news-live-b1995038.html#post-542079</a></p><p>As always, thank you for taking the time to read this. Please stay safe!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6b61010120d6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-january-18-2022-6b61010120d6">Weekly Covid-19 Update: Tuesday, January 18, 2022</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, January 11, 2022]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-january-11-2022-3cdb8686ac6c?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/3cdb8686ac6c</guid>
            <category><![CDATA[coronavirus-research]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid-19-update]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 11 Jan 2022 22:50:42 GMT</pubDate>
            <atom:updated>2022-01-12T10:01:12.157Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. This week I have information on T-cells from the common cold fighting Covid, the amount of time the virus stays infectious in the air, research on the effectiveness of travel restrictions, false-positive rapid lateral flow tests, long Covid, the meaning of endemic and where we are in that regard, and of course a world update. I hope you find this information useful.</p><p>1) A peer-reviewed study published in the journal <em>Nature Communications</em> showed that T-cells from the common cold can provide protection against Covid-19 infection. As a reminder, T-cells are white blood cells that help to determine our immune response to foreign substances in the body. The study analyzed household contacts of those diagnosed with Covid-19 to try to understand their immune responses. Household contacts were given PCR tests when the household member tested positive, then again at days four and seven. Their blood was also taken so that the researchers could determine their levels of pre-existing T-cells from the common cold. Of the study’s sample, half of the contacts became infected with Covid-19, while the other half did not. Those who did not test positive for Covid were found to have significantly higher levels of cross-reactive T-cells. The researchers also found that the T-cells attacked the internal proteins within Covid rather than the spike protein (which is what vaccines target). The study stated that their findings supported the potential of developing vaccines which target the core proteins in Covid. In a news article the researchers warned that no one should rely on T-cells from the common cold alone, and vaccination is still the best way to protect against Covid infection. You can read the full study here: <a href="https://www.nature.com/articles/s41467-021-27674-x">https://www.nature.com/articles/s41467-021-27674-x</a></p><p>2) Researchers from the University of Bristol in the UK developed equipment that allows them to test how long Covid can survive in the air under different conditions (e.g., heat, humidity, light). Results showed that within 20 minutes of becoming airborne Covid loses 90% of its ability to infect us. The study, which has not yet undergone peer review (important point!), stated that much of the loss of infectivity occurred during the first 5 minutes the virus was airborne. In environments with relative humidity (RH) lower than 50%, the virus lost its infectivity within about 5 seconds. In environments with higher humidity (around 90% or above) the virus was able to maintain its infectivity for longer, with about 52% of particles remaining infectious after 5 minutes. Temperature was not found to have any impact on the length of the virus’s infectivity. This research points to the importance of simple measures such as wearing masks and social distancing in reducing the spread of Covid. You can read the pre-print of the study here: <a href="https://www.medrxiv.org/content/10.1101/2022.01.08.22268944v1.full.pdf">https://www.medrxiv.org/content/10.1101/2022.01.08.22268944v1.full.pdf</a></p><p>3) A peer-reviewed study published in <em>The Lancet Regional Health</em> examined travel restrictions and policies (such as required quarantines and Covid-19 testing) implemented by several nations throughout the pandemic. Using modeling, the researchers sought to determine which quarantine and testing strategies would prevent transmission of the virus to the same extent as a total travel ban. The analysis was based on travel between 26 European countries in November 2021 (e.g., traveling from country A to country B; country A to country C, etc.) Results showed that for nearly half of the European country pairs, no test or quarantine was necessary to prevent increased transmissions in the destination country. For other travel scenarios a test but no quarantine was sufficient, and in some scenarios a quarantine for a few days with a test upon exit was sufficient. The paper stated that this model can be used by national governments to account for country-specific characteristics in order to set policies regarding travel restrictions based on the traveler’s country of origin. Strategies could be adjusted over time depending on each country’s specific circumstances. The authors concluded, “Border closure would be recommended during very early stages of pandemic spread to limit the global dissemination of an emerging disease from the epicentre, but such a measure provides limited benefits once community transmission is established in the country … Use of our model can provide an evidence-based approach to ameliorate policy decisions that often otherwise result in polarised, entirely permissive or overly restrictive states.” You can read the full study here: <a href="https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00290-8/fulltext#seccesectitle0001">https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00290-8/fulltext#seccesectitle0001</a></p><p>4) As more and more people are relying on the use of rapid antigen (lateral flow) tests, researchers in Canada sought to understand the extent to which rapid tests produce false-positive results. Using data from workers who were required to test regularly for their jobs, every person who tested positive on a rapid test was then required to take a more sensitive/accurate PCR test. Over 900,000 rapid tests were conducted in 537 workplaces, of which 0.05% were found to be false positives. Of those, 60% were found to be from the same batch of a specific test — Abbott’s Panbio COVID-19 Ag Rapid Test Device — which the study’s authors noted was likely due to manufacturing issues. The authors noted that the “overall rate of false-positive results among the total rapid antigen test screens for SARS-CoV-2 was very low, consistent with other, smaller studies” and stated that the results highlight the need for comprehensive data systems to quickly identify issues, such as the batch issue identified in their study. They also pointed out that aside from batch issues, “false-positives are possible due to the timing of the test (ie, too early or too late in the infectious stage) or quality issues in how the self-test was completed.” This study was published in the journal <em>JAMA</em>. You can read the full text of it here: <a href="https://jamanetwork.com/journals/jama/fullarticle/2788067">https://jamanetwork.com/journals/jama/fullarticle/2788067</a></p><p>5) Let’s talk about long Covid. New data from the UK Office of National Statistics (ONS) showed that an estimated 1.3 million people in the UK (2% of the population) are currently living with long Covid, defined as symptoms persisting for more than four weeks after infection. Long Covid was more prevalent in people aged 35–69, females, people living in more deprived areas, those with an activity-limiting health condition or disability, and those who work in health care, social care, or teaching/education (the latter saw the highest month-on-month increase in the prevalence of long Covid out of any job category). The most common symptom amongst those with long Covid was fatigue (51%), followed by loss of smell (37%), shortness of breath (36%), and difficulty concentrating (28%). The report noted that long Covid is still “an emerging phenomenon that is not yet fully understood” and that the length of one’s recovery from Covid is not necessarily related to how severe one’s case was or whether they had been hospitalized. You can read the full report here: <a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6january2022">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6january2022</a></p><p>6) While this point does not review a research study, I’ve seen quite a lot of news articles and social media conversations recently about when Covid-19 will become endemic. I think it’s useful to review what that term actually means and to recap some of the reports from global health experts about this topic. According to the Communicable Disease Control Handbook, a virus is considered endemic when there are “persistent, low or moderate levels of disease” in a given geographical location. In contrast, the WHO states that a pandemic is “when a disease’s growth is exponential. This means growth rate skyrockets, and each day cases grow more than the day prior.” Considering that on January 10, 2022 we hit the highest number of daily infections globally since the pandemic began (3.2 million) and many nations continue to set daily records for new infections, it does not appear that we are nearing endemic levels anytime soon. According to an article by Columbia University’s School of Public Health, when a virus becomes endemic the disease spread and rates are predictable; it is not defined by the severity of the disease but rather the degree to which is spreads. Meanwhile, a pandemic “cuts across international boundaries, as opposed to regional epidemics”. Indeed, Covid is still spreading globally and is not confined to a region or a few regions at the moment. In a press conference today, Dr Catherine Smallwood, a senior emergency officer at the WHO, said, “We still have a huge amount of uncertainty, we still have a virus that’s evolving quite quickly and posing quite new challenges. So we’re certainly not at the point of being able to call it endemic. It may become endemic in due course, but pinning that down to 2022 is a little bit difficult at this stage.” Similarly, Dr. Peter English, a retired Public Health England consultant, stated in an interview with Sky News that more variants will continue to emerge and there is no way to predict how transmissible or severe these variants will be. Based on all of that information, it does not seem realistic to expect that we will be entering an endemic state anytime soon.<br>(*Note — in the original version of this post I said there were 15.5 million cases in a day globally; that was the weekly total. The post has been updated with the highest daily total at 3.2 million.)<br>Sources:<br>Columbia University article: <a href="https://www.publichealth.columbia.edu/public-health-now/news/epidemic-endemic-pandemic-what-are-differences">https://www.publichealth.columbia.edu/public-health-now/news/epidemic-endemic-pandemic-what-are-differences</a><br>Global Covid-19 case numbers via the WHO: <a href="https://covid19.who.int/">https://covid19.who.int/</a> <br>News article about the WHO press conference: <a href="https://www.telegraph.co.uk/global-health/science-and-disease/covid-nowhere-near-endemic-virus-remains-unpredictable-warns/">https://www.telegraph.co.uk/global-health/science-and-disease/covid-nowhere-near-endemic-virus-remains-unpredictable-warns/</a><br>News article via Sky News: <a href="https://news.sky.com/story/covid-when-will-the-uk-transition-from-pandemic-to-endemic-and-how-would-we-learn-to-live-with-coronavirus-12512882">https://news.sky.com/story/covid-when-will-the-uk-transition-from-pandemic-to-endemic-and-how-would-we-learn-to-live-with-coronavirus-12512882</a></p><p>7) Now for your world update. I’ll start with the US, where the number of new cases yesterday hit 1.43 million, the highest number since the pandemic started. Additionally, hospitalizations in the US are at an all-time high since the pandemic began with 135,559 in hospital as of today. Daily case numbers are up 204%, hospitalizations are up 83%, and deaths are up 36% over the past two weeks. In terms of hospitalizations per capita, Washington DC leads the way with 878 hospitalizations per 100K people. New Jersey is second, followed by New York, Ohio, Delaware, and Maryland. In terms of cases per capita, Rhode Island is currently the highest with 418 per 100K, followed by New York, New Jersey, Massachusetts, and Connecticut.<br> — In the UK there were 120,821 new cases today. Over the past two weeks there has been a 58% increase in cases and an 80% increase in deaths. The latest figures I could find in terms of hospitalization rates were from last week, when hospitalizations had increased 75% on the previous week. There are currently 19,828 people in hospital in the UK, which is nearly 3,500 more than this time last week.<br> — Elsewhere both France and Italy reported record numbers of new cases today with 368,149 and 220,532, respectively. Turkey also reported a record number of cases today with 74,266 new infections. In today’s WHO press conference, Dr. Hans Kluge, the Regional Director for Europe, said that forecasting shows that more than 50% of the population in Europe could contract the Omicron variant in the next two months.<br>Sources:<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a><br>UK numbers: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a> and <a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/hospitals</a><br>Europe info: <a href="https://www.theguardian.com/world/live/2022/jan/11/covid-news-live-pfizer-says-omicron-specific-vaccine-could-be-available-by-march-mexico-president-tests-positive-again?filterKeyEvents=false&amp;page=with:block-61dddae08f0841d0f6ca6d0b#block-61dddae08f0841d0f6ca6d0b">https://www.theguardian.com/world/live/2022/jan/11/covid-news-live-pfizer-says-omicron-specific-vaccine-could-be-available-by-march-mexico-president-tests-positive-again?filterKeyEvents=false&amp;page=with:block-61dddae08f0841d0f6ca6d0b#block-61dddae08f0841d0f6ca6d0b</a></p><p>That’s all for this week. Please keep staying safe out there. I’ll be back next week with another update.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3cdb8686ac6c" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-january-11-2022-3cdb8686ac6c">Weekly Covid-19 Update: Tuesday, January 11, 2022</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, January 4, 2022]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-january-4-2022-cabd946c2d0e?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/cabd946c2d0e</guid>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[omicron]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 04 Jan 2022 23:37:18 GMT</pubDate>
            <atom:updated>2022-01-04T23:37:18.684Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday and Happy New Year, everyone. If you had told me back in May of 2020 when I first started writing these updates that I would still be doing them in 2022 I would’ve thought you were crazy. But here we are. Without further ado, your Covid research update for this week:</p><p>1) In case anyone out there is still not convinced of the effectiveness of masks in helping to prevent transmission of Covid-19, a new research study conducted in pre-schools and schools in Germany showed that Covid outbreaks were “effectively contained by an obligation for adults and children to wear face masks.” While the majority of outbreaks identified in the study started with a child as the index (original) case, when an adult (such as a teacher) was found to be the index case, there was a greater number of secondary infections (people infected by the index case). In schools with mandatory mask requirements for both adults and children, there was a significant decrease in the number of secondary cases. The researchers recommended that adults working in schools should be required to wear masks in order to help contain Covid outbreaks within the school. The study was peer-reviewed and published in <em>Frontiers in Public Health</em>. You can read the full article here: <a href="https://www.frontiersin.org/articles/10.3389/fpubh.2021.780039/full#h3">https://www.frontiersin.org/articles/10.3389/fpubh.2021.780039/full#h3</a></p><p>2) Researchers explored whether pregnant women who were vaccinated against Covid-19 were more likely to deliver their babies prematurely than those who were not vaccinated. The researchers studied over 46,000 pregnancies, 10,064 of which were in women who were vaccinated, and found no differences between premature births of babies born to vaccinated and unvaccinated women. The baby’s weight was also no different based on the mother’s vaccination status. The report noted that previous research showed a link between pregnant women <em>infected</em> with Covid and pre-term birth as well as evidence that vaccinated pregnant women were able to pass on antibodies to their infant, both points further justifying the need for pregnant women to be vaccinated. The study concluded, “evidence of the benefits of COVID-19 vaccination during pregnancy continues to accrue, including the detection of antibodies in cord blood. Together, these findings reinforce the importance of communicating the risks for COVID-19 during pregnancy, the benefits of vaccination, and information on the safety and effectiveness of COVID-19 vaccination during pregnancy.” The study was published in the CDC’s <em>Morbidity and Mortality Weekly Report</em> and can be read in full here: <a href="https://www.cdc.gov/mmwr/volumes/71/wr/mm7101e1.htm?s_cid=mm7101e1_w">https://www.cdc.gov/mmwr/volumes/71/wr/mm7101e1.htm?s_cid=mm7101e1_w</a></p><p>3) A study examined the T-cell responses of individuals who were either vaccinated or had previously been infected by Covid to assess whether T-cells will provide protection against the Omicron variant. T-cells are white blood cells that originate in the bone marrow and help to determine our immune response to foreign substances in the body. The study concluded that T-cell responses elicited by vaccines or previous infection should offer protection against Omicron. The study noted, however, that T-cells will not necessarily prevent infection, but they should help to protect people against significant illness from Omicron. The study was peer-reviewed and published in the journal <em>Viruses</em>. You can read the full text here: <a href="https://www.mdpi.com/1999-4915/14/1/79/htm">https://www.mdpi.com/1999-4915/14/1/79/htm</a></p><p>4) A study which has not yet undergone peer review (important disclaimer) examined household transmissions of the Omicron variant compared to the Delta variant in nearly 12,000 households in Denmark. When the initial case was with the Omicron variant, 31% of households had at least one other household member test positive, compared to just 21% for the Delta variant. The study found that transmission rates for both variants were highest amongst those who were unvaccinated. Among the vaccinated, those who had a booster dose of the vaccine were less likely to catch the Omicron variant than those who only had two doses of the vaccine. They also found that Omicron was between 2.7–3.7 times more transmissible than Delta in vaccinated individuals. For unvaccinated people, though, there was no difference in transmissibility between the two variants, which led the researchers to conclude that Omicron’s transmissibility was due to its ability to evade immune responses rather than an inherent increase in its basic transmissibility. You can read the pre-print of the study here: <a href="https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1.full.pdf">https://www.medrxiv.org/content/10.1101/2021.12.27.21268278v1.full.pdf</a></p><p>5) A study that is currently under peer-review at the journal Nature Portfolio studied several different Covid-19 variants in mice and hamsters to better understand how different variants affected the body. Results showed that when infected with the Omicron variant, the animals experienced less lung damage, lost less weight, and were less likely to die than with previous variants. One specific type of hamster, the Syrian hamster, became severely ill when infected with previous variants of the virus but experienced much more mild symptoms with Omicron. These findings were consistent with initial research on humans infected with Omicron. You can read the pre-print of the study here: <a href="https://www.researchsquare.com/article/rs-1211792/v1">https://www.researchsquare.com/article/rs-1211792/v1</a></p><p>6) Preliminary findings from a clinical trial of the Johnson &amp; Johnson vaccine as a booster dose against Omicron showed that it reduced the risk of hospitalization by 85%. The study involved 69,062 healthcare workers who were given the J&amp;J booster (second dose of that vaccine) between 6–9 months after receiving their initial dose. The findings from the booster group were compared to those from a similar group of individuals who were not vaccinated. The researchers concluded that the findings were especially important for the continent of Africa, which has been very reliant on the J&amp;J vaccine thus far in the pandemic. The study has not yet undergone peer review and the pre-print can be read here: <a href="https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1">https://www.medrxiv.org/content/10.1101/2021.12.28.21268436v1</a></p><p>7) Now for your world update. Yesterday the US had over 1 million new cases of Covid-19 for the first time ever in the pandemic. The total number of people testing positive was 1,017,376. Daily cases have increased 239% over the past two weeks and the average daily number of cases is nearly half a million. Hospitalizations have increased 41% in the same time period and deaths have decreased by 3%. The hardest-hit states/territories in terms of cases per capita at the moment include New York, New Jersey, Washington D.C., Puerto Rico, US Virgin Islands, Delaware, Massachusetts, Florida, Maryland, and Rhode Island. <br> — The UK also just hit a record for its number of daily cases with 218,724. Over the past two weeks the number of daily cases has increased 109%. Deaths have increased 14% over that time and hospitalizations are also on the rise, with several hospitals declaring critical incidents (meaning they are concerned they will not be able to provide priority services such as treatments for cancer patients or heart disease patients). <br> — Elsewhere, Italy and France both reported record numbers of new cases today with 170,844 and 271,686, respectively. Israel’s Prime Minister announced today that a study there showed a fourth dose of a Covid vaccine provided a five-fold boost in antibodies, although I have not yet been able to find the actual study (or a summary of it). Australia also recorded a record number of cases today at 47,799.<br>Sources:<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a><br>UK numbers: <a href="https://www.theguardian.com/world/coronavirus-outbreak">https://www.theguardian.com/world/coronavirus-outbreak</a><br>World news: <a href="https://www.theguardian.com/world/live/2022/jan/04/covid-live-news-chinese-city-puts-13-million-in-strict-lockdown-over-three-asymptomatic-cases">https://www.theguardian.com/world/live/2022/jan/04/covid-live-news-chinese-city-puts-13-million-in-strict-lockdown-over-three-asymptomatic-cases</a> <br>Australia numbers: <a href="https://www.reuters.com/world/asia-pacific/australias-covid-19-cases-surge-hospitalisations-hit-pandemic-high-nsw-2022-01-03/">https://www.reuters.com/world/asia-pacific/australias-covid-19-cases-surge-hospitalisations-hit-pandemic-high-nsw-2022-01-03/</a></p><p>That’s all for this week. I hope everyone’s 2022 is off to a good start. Thanks for reading and I’ll be back next week with another update.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=cabd946c2d0e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-january-4-2022-cabd946c2d0e">Weekly Covid-19 Update: Tuesday, January 4, 2022</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, December 28, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-december-28-2021-7d3b267990ec?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/7d3b267990ec</guid>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <category><![CDATA[omicron]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Wed, 29 Dec 2021 00:06:22 GMT</pubDate>
            <atom:updated>2021-12-29T00:06:22.467Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. I nearly forgot to write a post today (I’m in full-on holiday mode at the moment), but when I saw the news that there were record numbers of cases in the US, UK, France, Portugal, Australia, and Greece today I was quickly reminded and managed to put a little something together. Without further ado, your final Covid research update of 2021.</p><p>1) Researchers tested the Omicron Covid variant against a wide variety of treatments, vaccines, previous infections, and vaccine boosters. The basic finding was that booster vaccines were most effective in fighting Omicron. When tested against nine different monoclonal antibody treatments (such as the ones developed by Eli Lilly and Regeneron), Omicron was partially or totally resistant to all of them. In terms of vaccines, the researchers tested Omicron against the blood of people who had received two doses of either Pfizer or AstraZeneca five months ago. Neither vaccine was found to be effective against Omicron after that amount of time. When testing the blood of individuals who had received a Pfizer booster dose one month ago, though, there was a strong increase in neutralizing activity (although not as strong as when tested against the Delta variant of Covid). They also studied Omicron against the blood of people who had been infected with Covid either 6 months or 12 months prior. Only 36% and 39% of the samples showed a neutralizing response, but when testing the blood of previously infected individuals who had recently received a booster vaccine dose, the neutralizing activity was much higher. The authors concluded, “A booster dose significantly improves the quality and the level of the humoral immune response, and is associated with a strong protection against severe forms of the disease. An accelerated deployment of vaccines and boosters throughout the world is necessary to counteract viral spread.” This article was peer-reviewed and has been accepted for publication in the journal Nature. You can read the full text here: <a href="https://www.nature.com/articles/d41586-021-03827-2">https://www.nature.com/articles/d41586-021-03827-2</a><br>A second study, also peer-reviewed and accepted for publication in Nature, found virtually the exact same things. That study can be read here: <a href="https://www.nature.com/articles/d41586-021-03825-4">https://www.nature.com/articles/d41586-021-03825-4</a></p><p>2) A study published by Imperial College London examined the hospitalization and vaccination records of 56,000 people who tested positive for the Omicron variant of Covid-19 and 269,000 people who tested positive for Delta. The findings showed that those infected with Omicron had a 20–25% lower risk of visiting a hospital than those infected with Delta, and a 40–45% lower risk of staying in the hospital for at least one night. For those who were never previously infected with Covid and had never been vaccinated, the risk of hospitalization with Omicron was only 11% lower than with Delta. Those who had been previously infected with Covid had a 50% lower chance of hospitalization and a 61% lower risk of having to stay in the hospital at least one night. The authors noted that more data is necessary, specifically on older populations where Omicron was not yet widespread at the time the research was conducted. You can read the full report here: <a href="https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf">https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf</a></p><p>3) Another study focused on hospitalizations with Omicron showed that when individuals actually <em>were </em>hospitalized with this variant, their risk of severe disease was no different from those individuals who were hospitalized with Delta. Similar to the study outlined in point number two, though, the risk of hospitalization was lower in the population studied. This study was based on data from Covid-positive cases in South Africa between October to December 2021. The study has not yet undergone peer review, which is an important disclaimer, but the pre-print can be read in full here: <a href="https://www.medrxiv.org/content/10.1101/2021.12.21.21268116v1">https://www.medrxiv.org/content/10.1101/2021.12.21.21268116v1</a></p><p>4) In treatment news, the Food and Drug Administration in the US approved two antiviral pills for use against Covid-19 last week. One of the drugs, called Paxlovid, is manufactured by Pfizer and can be taken at home to help battle the worst effects of the virus. It was approved for those aged 12 or older who have a positive Covid-19 test and symptoms. The second pill, molnupiravir, is manufactured by Merck and was approved for use in those aged 18 and older. According to a news article by the Associated Press, both are thought to be effective against the Omicron variant and that “Pfizer’s drug is all but certain to be the preferred option because of its mild side effects and superior effectiveness, including a nearly 90% reduction in hospitalizations and deaths among patients most likely to get severe disease.”<br> You can read a press release from the FDA about Paxovid here: <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19</a><br>And a press release about the Merck pill here: <a href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain</a> <br>And the AP article here: <a href="https://apnews.com/article/coronavirus-pandemic-pfizer-medication-f5f65e7e61d6aa9c7dfa193053e8878a">https://apnews.com/article/coronavirus-pandemic-pfizer-medication-f5f65e7e61d6aa9c7dfa193053e8878a</a></p><p>5) Speaking of those antiviral pills, a peer-reviewed article was published in the journal Science focusing on molnupiravir and the length of time someone with Covid-19 remained infectious. In the controlled, randomized, multicenter clinical trial involving 202 non-vaccinated individuals, molnupiravir was given in three different doses and some participants received a placebo. For those receiving the highest dose of molnupiravir (800mg), infectious virus was detected in only 1.9% of patients after three days of treatment compared with 16.7% of the placebo group. At day five of treatment, no detectable virus was found in patients receiving either 400mg or 800mg of the drug, compared to 11.1% of those receiving the placebo. The authors concluded that the study “provides strong biological evidence supporting development of molnupiravir as an oral agent to reduce infectious virus replication and interrupt progression of COVID-19 during early stages of disease.” You can read the full text of the study here: <a href="https://www.science.org/doi/10.1126/scitranslmed.abl7430">https://www.science.org/doi/10.1126/scitranslmed.abl7430</a></p><p>6) In other treatment news, a peer-reviewed study published in The New England Journal of Medicine tested the use of the drug remdesivir in symptomatic, non-hospitalized Covid-19 patients who were at higher risk for disease progression (they were either aged 60+, obese, or had other existing medical conditions such as diabetes or hypertension). The study involved 562 patients who received either remdesivir or a placebo. A three-day course of remdesivir resulted in an 87% lower risk of hospitalization in the experimental group than in the placebo group. The remdesivir group also had an 81% lower risk of Covid-19 related medical visits or death after 28 days than those in the placebo group. You can read the full study here: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116846?query=featured_coronavirus">https://www.nejm.org/doi/full/10.1056/NEJMoa2116846?query=featured_coronavirus</a></p><p>7) Now for a world update. Today in the US the number of new cases reported was 543,4154, the highest it’s ever been since the pandemic began. This number is likely to be inflated due to a delay in testing data from Christmas. Still, there has been a 105% increase in new daily cases over the past two weeks. Hospitalizations are currently up 5% and deaths have decreased by 6% over the past two weeks. The current hottest hot spot in the US is Washington, D.C., with a 984% increase in daily infections over the past two weeks. DC is currently experiencing 279 cases per 100K people. Per capita, the next highest states in terms of infections include New York, New Jersey, Rhode Island, Illinois, Florida, Maryland, Connecticut, Ohio, Massachusetts, and Delaware. Yesterday the US Centers for Disease Control and Prevention (CDC) lowered the number of days an infected person needs to self-isolate from 10 to 5. <br> — The UK also experienced its highest number of daily new cases today with 129,471, and that only includes data from England and Wales, so the actual number will be higher when Scotland and Northern Ireland’s data can be added. The UK has experienced a 111% increase in daily cases over the past two weeks. Deaths are down 11% over the past two weeks. Hospitalisations over the week leading up to Christmas were up by 44%, and in London that number was a 68% increase. Over 500 children were admitted to hospital in the week leading up to Boxing Day.<br> — Elsewhere, France (179,807), Portugal (17,172), Greece (21,657), and Australia (11,264) all reported their highest number of daily cases of the whole pandemic today. Denmark reported its highest number of cases yesterday (41,035) and currently has the world’s highest per capita infection rate with 1,612 cases per 100K people. Nations all over the world are imposing new restrictions in attempts to curb infections.<br> US data: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br> CDC information: <a href="https://www.nytimes.com/live/2021/12/28/world/omicron-covid-vaccine-tests/cdc-isolation-airlines">https://www.nytimes.com/live/2021/12/28/world/omicron-covid-vaccine-tests/cdc-isolation-airlines</a> <br> UK data: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a> and <a href="https://www.independent.co.uk/news/omicron-symptoms-covid-tests-restrictions-live-b1983135.html">https://www.independent.co.uk/news/omicron-symptoms-covid-tests-restrictions-live-b1983135.html</a> <br> The rest of the world: <a href="https://www.theguardian.com/world/live/2021/dec/28/covid-live-news-travel-chaos-as-3500-more-flights-suspended-fresh-curbs-in-france">https://www.theguardian.com/world/live/2021/dec/28/covid-live-news-travel-chaos-as-3500-more-flights-suspended-fresh-curbs-in-france</a></p><p>That’s all for this week. Stay safe out there on New Year’s Eve and I’ll be back in the new year with further updates.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7d3b267990ec" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-december-28-2021-7d3b267990ec">Weekly Covid-19 Update: Tuesday, December 28, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, December 21, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-december-21-2021-a0136d5ae7cc?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/a0136d5ae7cc</guid>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[omicron]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 21 Dec 2021 19:27:41 GMT</pubDate>
            <atom:updated>2021-12-21T19:27:41.618Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. In this week’s update I have much more information on Omicron, the symptoms of Omicron, findings out of South Africa where Omicron caused a massive fourth wave of Covid, more info on vaccines, and a study on an antiviral drug. In the past I’ve been very careful to include a majority of peer-reviewed research articles in these updates, but due to the fast-moving nature of Omicron most of the research below has not had adequate time to undergo peer review, so please note that most of these findings are preliminary and still need to go through that very important process.</p><p>1) Researchers at the University of Hong Kong studied the Omicron, Delta, and original Covid-19 variants to understand how they affected the human bronchi (large tubes in your chest that carry air to your lungs) and the lungs. Findings showed that Omicron replicated approximately 70 times faster in the bronchi than either the Delta or original Covid (which could explain why it seems to spread more quickly than previous variants), but it replicated more than 10 times slower in human lung tissue. This may suggest that the Omicron variant is less severe than previous variants, although this obviously needs to be confirmed in follow-up studies. The paper is currently under peer review for publication and a summary of the study can be found here: <a href="https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection">https://www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection</a></p><p>2) In case you haven’t yet seen a list of symptoms for Omicron, an article published in the British Medical Journal (BMJ) outlined the top five symptoms based on Omicron cases in the UK. They include runny nose, headache, fatigue (mild or severe), sneezing, and sore throat. Another report out of South Africa based on data from 78,000 confirmed Omicron infections said that the most common early signs of Omicron were a scratchy throat, nasal congestion, a dry cough, and myalgia manifesting in lower back pain. You can read the BMJ article here: <a href="https://www.bmj.com/content/375/bmj.n3103">https://www.bmj.com/content/375/bmj.n3103</a> and a news article about the South African findings here: <a href="https://www.telegraph.co.uk/global-health/science-and-disease/lower-back-pain-scratchy-throat-emerge-symptoms-omicron/">https://www.telegraph.co.uk/global-health/science-and-disease/lower-back-pain-scratchy-throat-emerge-symptoms-omicron/</a></p><p>3) In another study by South Africa’s Discovery Health based on 211,000 confirmed Omicron cases, researchers found that two doses of the Pfizer vaccine provided just 33% protection against infection from Omicron, but 70% protection against hospitalization. This protection against hospitalization was true for all age groups over 18 as well as those with comorbidities such as diabetes, hypertension, and other cardiovascular diseases. The research also found that for those who previously had Covid, the risk of reinfection with Omicron was significantly higher than with previous variants. For those who had been infected with Delta, the risk of reinfection was 40% and for those with the Beta variant (also known at the time as the “South African variant”) the risk was 60%. Next, the study reported that Omicron spreads much more quickly, but resulted in fewer cases of severe disease and hospitalizations than previous variants (which could be due to high levels of previous infection and vaccinations; everything I’ve read indicates it is too early to say it is definitely less severe). Finally, amongst children the findings showed that “children under age 18 have a 20% higher risk of admission for complications of COVID-19 when infected with Omicron”. You can read the full report here: <a href="https://www.discovery.co.za/corporate/news-room">https://www.discovery.co.za/corporate/news-room</a></p><p>4) A new study published in The Lancet studied the AstraZeneca and Pfizer two-dose vaccines against the original Covid strain (known as “Victoria”), as well as the Beta, Delta, and Omicron variants. Findings showed a significant decrease in efficacy for both vaccines against Omicron, especially in the AstraZeneca vaccine, where all but one study participant’s neutralizing titres dropped below the threshold for detection (in layman’s terms, two doses of the AZ vaccine did not work against Omicron). The authors noted that there is likely to be an increase in breakthrough infections in individuals who have only received two doses of a vaccine, which could drive a new wave of infection. This seems to point to the findings of several studies from last week’s write-up, which stressed the importance of booster doses. You can read the full report here: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02844-0/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02844-0/fulltext</a></p><p>5) Speaking of boosters, yesterday Moderna announced the results of tests using its vaccine as a booster. In the small-scale study, several different dosage levels were tested in groups of 20 people. By day 29 after receiving the booster, the 50-microgram dose and 100-microgram dose groups both experienced sharp increases in neutralizing antibodies against Omicron (37-fold and 80-fold, respectively). The company now plans to expand its study using up to 600 participants. The data from this study has not yet undergone peer review. You can read more about it via this article from Reuters: <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-says-booster-dose-its-covid-19-vaccine-appears-protective-vs-omicron-2021-12-20/">https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-says-booster-dose-its-covid-19-vaccine-appears-protective-vs-omicron-2021-12-20/</a> and this article from the New York Times: <a href="https://www.nytimes.com/2021/12/20/health/moderna-covid-booster-omicron.html?referringSource=articleShare">https://www.nytimes.com/2021/12/20/health/moderna-covid-booster-omicron.html?referringSource=articleShare</a></p><p>6) In other vaccine news, Pfizer recently announced the results of their Phase II/III trial in children aged 6 months to 5 years. While the vaccines were shown to be safe with no severe events in the trial participants, the dosage used was only found to be effective in children between 6 months and under 2 years old. As the dosage was not effective in those ages 2–5, Pfizer is now testing a third dose of the vaccine equal to the one received in the first two doses rather than testing a higher dose. If this is successful they will seek authorization to use a three-dose vaccine series sometime in the first half of 2022. You can read Pfizer’s press release about it here: <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19</a> and an insightful piece by epidemiologist Dr. Katelyn Jetelina here: <a href="https://yourlocalepidemiologist.substack.com/p/why-did-the-pfizer-young-kids-trial">https://yourlocalepidemiologist.substack.com/p/why-did-the-pfizer-young-kids-trial</a></p><p>7) In Covid treatment news, a peer-reviewed study published in The New England Journal of Medicine reported the results of a phase 3, double-blind, randomized, placebo-controlled trial of an antiviral drug called molnupiravir, developed by drugmaker Merck. They tested the drug on nonhospitalized, unvaccinated adults with at least one risk factor for severe Covid within 5 days of the onset of symptoms. Of the participants, 716 received the drug and 717 received a placebo. The risks of both hospitalization and death were lower in the group that received molnupiravir. The researchers concluded that the drug was effective and safe for this population. You can read the full study here: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2116044?query=featured_coronavirus">https://www.nejm.org/doi/full/10.1056/NEJMoa2116044?query=featured_coronavirus</a></p><p>8) Now for your world update. In the US, Omicron has become the dominant variant. (Side note — to my US friends, take it from those of us in the UK, this thing travels FAST and even boosters aren’t a fool proof way of avoiding it. We found that out in my household today!) Yesterday the US had 276,389 new cases, but the 14-day average is 143,164, which is a 20% increase over the past two weeks. Hospitalizations are up 14% and deaths have increased 3%. The top 10 states in terms of infections per capita include Rhode Island, New Hampshire, New York, Ohio, Illinois, Massachusetts, New Jersey, Delaware, Wisconsin, and Vermont (Indiana, you’re number 11). Today President Biden announced he will make 500 million rapid tests free for the public beginning in January. Another side note — we have had access to free rapid tests in the UK for quite some time and I can say they are VERY useful! <br> — In the UK Omicron continues to surge, as there were 90,629 new cases today and over the past two weeks there has been a 78% increase in cases. London is the current hot spot per capita with a 269% increase in cases over the past 14 days. The booster vaccine rollout continues to go well with 897,979 doses administered today. Tonight Prime Minister Boris Johnson announced there would be no new Covid restrictions prior to Christmas.<br> — Elsewhere, New Zealand has delayed its border opening until the end of February due to concerns about Omicron, and in Australia the state of New South Wales recorded its highest ever single-day case number at 3,057. Portugal ordered nightclubs and bars to shut down, announced that people should work from home from at least December 26 — January 9, and are limiting New Year’s Eve celebrations to no more than 10 people per group outdoors to help control the spread of Covid. Sweden also urged people to work from home and is requiring seated-only service at bars, restaurants and large public events.<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br>UK numbers: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a> and <a href="https://www.bbc.co.uk/news/uk-51768274">https://www.bbc.co.uk/news/uk-51768274</a> <br>NZ &amp; AUS info: <a href="https://edition.cnn.com/world/live-news/omicron-variant-coronavirus-news-12-20-21-intl/index.html">https://edition.cnn.com/world/live-news/omicron-variant-coronavirus-news-12-20-21-intl/index.html</a> <br>Portugal and Sweden: <a href="https://www.theguardian.com/world/live/2021/dec/21/covid-news-live-who-declares-2022-to-be-the-year-we-end-the-pandemic-as-us-says-omicron-is-now-dominant-strain?filterKeyEvents=false&amp;page=with:block-61c1d9648f08d3319b5d7ed0#block-61c1d9648f08d3319b5d7ed0">https://www.theguardian.com/world/live/2021/dec/21/covid-news-live-who-declares-2022-to-be-the-year-we-end-the-pandemic-as-us-says-omicron-is-now-dominant-strain?filterKeyEvents=false&amp;page=with:block-61c1d9648f08d3319b5d7ed0#block-61c1d9648f08d3319b5d7ed0</a></p><p>That’s all for this week. Merry Christmas to those of you who celebrate and I hope everyone stays safe and tests negative this holiday season! I’ll be back with another update next Tuesday.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a0136d5ae7cc" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-december-21-2021-a0136d5ae7cc">Weekly Covid-19 Update: Tuesday, December 21, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Wednesday, December 15, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-wednesday-december-15-2021-9e9a6b66f931?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/9e9a6b66f931</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[omicron]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Wed, 15 Dec 2021 17:48:16 GMT</pubDate>
            <atom:updated>2021-12-15T17:48:16.210Z</atom:updated>
            <content:encoded><![CDATA[<p>Apologies for my absence from these reports. The last two months have been absolutely insane from a work and personal life perspective. I’ve been reading so much about Omicron lately and thought I should try to do at least a brief update! I will try to get back to doing these every Tuesday for a while moving forward. Without further ado, here is the latest in Covid-related research and news.</p><p>1) The first thing on most of your minds is probably whether vaccines are effective against the new Omicron variant. Remember that research takes time and we are still in the early days of this variant, but there are some initial findings to report. I’ll include these in points 1, 2, and 3 of this update. First, a very small study out of South Africa, which has not yet been peer reviewed, studied 12 people infected with Omicron (6 with no previous infection, 6 with previous infection, all vaccinated with Pfizer). In those with two doses of Pfizer but no previous infection there was a 41-fold lower level of neutralizing antibodies than what was seen with previous variants of the virus. Those who were previously infected and vaccinated showed higher neutralization than those who were only vaccinated, suggesting that booster doses of the vaccine may help to reduce the risk of infection. The authors concluded, “Previous infection, followed by vaccination or booster is likely to increase the neutralization level and likely confer protection from severe disease in Omicron infection.” You can read the pre-print of the study here: <a href="https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf">https://www.ahri.org/wp-content/uploads/2021/12/MEDRXIV-2021-267417v1-Sigal.pdf</a></p><p>2) Another study conducted in Israel (and for which I cannot find a pre-print, so this information is based on multiple news articles) studied the blood of 20 people who were vaccinated five to six months ago and 20 people who received a booster dose of the vaccine within the last month. Researchers introduced the Omicron variant to the blood, and amongst those who received their vaccine 5–6 months ago there was no neutralization against the variant. For those who had recently received a booster dose, though, there was a large immune response. One of the study’s authors, Dr. Gili Regev-Yochay, said that their findings showed the booster dose was about four times less effective against Omicron than it was against the Delta variant. Still, this study provided some good news regarding the effectiveness of booster doses. You can read a news article about it from The Independent here: <a href="https://www.independent.co.uk/news/world/asia/booster-third-jab-omicron-covid-israel-b1974840.html">https://www.independent.co.uk/news/world/asia/booster-third-jab-omicron-covid-israel-b1974840.html</a> and another one from Reuters here: <a href="https://www.reuters.com/world/middle-east/israeli-study-finds-pfizer-covid-19-booster-protects-against-omicron-2021-12-11/">https://www.reuters.com/world/middle-east/israeli-study-finds-pfizer-covid-19-booster-protects-against-omicron-2021-12-11/</a></p><p>3) A report published by the UK Health Security Agency, which I believe is the largest real-world analysis thus far, compared 56,439 cases of Delta Covid infections with 581 cases of Omicron to help determine vaccine effectiveness against the new variant. After two doses of Pfizer, vaccine effectiveness against Omicron was only 30–40%, and for AstraZeneca there was an even greater reduction. In those who received a Pfizer booster dose, however, there were significant increases in protection against symptomatic infection. For those who initially received two doses of AstraZeneca, the Pfizer booster provided 70% protection and for those who initially received two doses of Pfizer, the booster provided 75% protection. These numbers are lower than the booster’s protection against the Delta variant (around 90%). The report also included data about transmission of the Omicron variant based on data about households and close contacts, finding that the risk of transmission was higher with Omicron cases than it was for Delta. You can read the full report here: <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf</a></p><p>4) A study published in The Lancet examined booster vaccine effectiveness amongst 2,878 participants in the study, all of whom received a third vaccine dose two to three months after their second vaccine dose of AstraZeneca or Pfizer. The study found that those who originally received AstraZeneca vaccines achieved antibody levels 25 times higher than controls when they received a Pfizer booster and 32 times higher when they received a full dose of a Moderna booster. For those who received their first two doses of Pfizer, they experienced an eightfold increase in antibodies after the Pfizer booster and an 11-fold increase when they received the full dose of the Moderna booster (note — I say “full dose” because in the UK when Moderna is used as a booster, it is only given as a half dose). The findings were similar across all age groups (ages 30–82 were involved in the study). You can read the full peer-reviewed study here: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext</a></p><p>5) Based on findings from a clinical trial conducted by Pfizer, it appears that the company’s antiviral pill to treat Covid, called PAXLOVID, is effective in preventing hospitalization and death. In a study of 2,246 high-risk Covid patients, the drug reduced the risk of hospitalization by 89% within three days of symptom onset and 88% within five days of symptoms. There were no deaths in the sample studied. In both high-risk and standard-risk patients, the drug was shown to result in a 10-fold decrease in the viral load when compared to a placebo drug. Pfizer also announced that its antiviral drug was expected to work against the new Omicron variant of Covid. The company is now seeking approval for the drug from the Food and Drug Administration in the US. You can read the company’s full press release about it here: <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results</a></p><p>6) A study published by a private nonprofit foundation that conducts independent research on health policies, The Commonwealth Fund, reported that Covid vaccinations in the United States prevented 1.1 million Covid deaths, 10.3 million hospitalizations, and nearly 40 million infections as of November 2021. The researchers utilized modelling taking into account the population demographics of the US, the prevalence of specific Covid variants over different time periods, and daily vaccine doses administered in the US. The study also estimated that without vaccines the daily death toll in the US alone could have reached 21,000 per day. The researchers concluded, “As the Omicron variant begins to spread and the Delta variant surge continues, our results point to the tremendous power of vaccination to reduce disease and death from COVID-19. Sadly, they also highlight the ongoing tragic consequences of failing to vaccinate every eligible American.” You can read the full study here: <a href="https://www.commonwealthfund.org/publications/issue-briefs/2021/dec/us-covid-19-vaccination-program-one-year-how-many-deaths-and?utm_source=twitter&amp;utm_medium=social&amp;utm_campaign=Improving+Health+Care+Quality">https://www.commonwealthfund.org/publications/issue-briefs/2021/dec/us-covid-19-vaccination-program-one-year-how-many-deaths-and?utm_source=twitter&amp;utm_medium=social&amp;utm_campaign=Improving+Health+Care+Quality</a></p><p>7) Now for a world update. In the US there were 116,687 new cases of Covid-19 yesterday and over the past two weeks the number of daily new cases has increased 46%. Hospitalizations are up 22% over the same time period and deaths have increased 40%. The US has now reached 800,000 total Covid deaths over the duration of the pandemic. The rate of cases amongst the unvaccinated are 5 times higher than the vaccinated, and deaths amongst the unvaccinated are 13 times higher. In terms of hot spots, Wisconsin leads the nation with the highest rate of cases per capita, followed by New Hampshire, Rhode Island, Maine, Michigan, Connecticut, Massachusetts, Indiana, and Pennsylvania. Amongst all age groups, 61% of Americans are fully vaccinated.<br> — Today the UK hit its highest daily number of cases EVER with 78,610. Between yesterday and today the number of new cases identified as Omicron increased 87% in England and 140% in Scotland. In a public briefing this evening Professor Chris Whitty, the government’s Chief Medical Advisor, said the UK currently has “two epidemics on top of one another” with Omicron cases rapidly increasing and Delta cases remaining flat. Dr Jenny Harries, the head of the UK Health Security Agency also said today that the Omicron variant is “probably the most significant threat we’ve had since the start of the pandemic”. Of all of those eligible for vaccines in the UK, 81.5% have been fully vaccinated and 43% have received a booster dose.<br> — Elsewhere, Australia’s state of New South Wales recorded its highest number of new daily cases in three months with 1,360. Of those, 110 were confirmed to be the Omicron variant. From today, NSW removed most Covid restrictions for unvaccinated people in the state. <br>US data: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br>UK data: <a href="https://www.theguardian.com/politics/live/2021/dec/15/uk-covid-live-news-coronavirus-omicron-boosters-vaccines-christmas-boris-johnson-latest-updates">https://www.theguardian.com/politics/live/2021/dec/15/uk-covid-live-news-coronavirus-omicron-boosters-vaccines-christmas-boris-johnson-latest-updates</a> and <a href="https://coronavirus.data.gov.uk/details/vaccinations">https://coronavirus.data.gov.uk/details/vaccinations</a> <br>Australian update: <a href="https://edition.cnn.com/2021/12/14/australia/australia-omicron-covid-outbreak-restrictions-intl-hnk/index.html">https://edition.cnn.com/2021/12/14/australia/australia-omicron-covid-outbreak-restrictions-intl-hnk/index.html</a></p><p>That’s all for today. I will try to be back on my regular day (Tuesday) next week with a new update!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=9e9a6b66f931" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-wednesday-december-15-2021-9e9a6b66f931">Weekly Covid-19 Update: Wednesday, December 15, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, October 19, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-october-19-2021-6ffe7a2e3a2b?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/6ffe7a2e3a2b</guid>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[covid-19-update]]></category>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 19 Oct 2021 13:52:46 GMT</pubDate>
            <atom:updated>2021-10-19T13:52:46.152Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. This week’s Covid research update is a bit shorter than normal, as I’ve been extremely busy with my new semester starting and teaching intensively and did not have much free time to work on this. In this week’s report I have information regarding healthcare costs in the US due to Covid hospitalizations, breakthrough infections in vaccinated healthcare workers, vaccine responses in people with multiple myeloma, the effectiveness of mix and match vaccines, effectiveness of vaccine lottery promotions in the US, and of course a world update.</p><p>1) In the first year of the pandemic (2020), many private health insurers in the United States waived cost sharing for expenses related to Covid-19 hospitalizations. Patients may have still been billed if their health insurance plan did not use waivers or if the waivers did not include all hospital-related care. Researchers sought to understand how much patients in the US paid for Covid-19 hospitalizations during this time period. Looking at data from 4,075 patients, they found 71.2% with private insurance and 49.1% with Medicare Advantage had to pay something out-of-pocket for any hospitalization-related service. The mean out-of-pocket expenses for each group were $788 and $277, respectively. Furthermore, 4.6% of private health insurance patients and 1.3% of Medicare patients had to pay at least some out-of-pocket expenses for facility services billed by hospitals. For these patients, the mean out-of-pocket expenses were $3,840 and $1,536, respectively. The authors cautioned that their findings indicate that out-of-pocket spending on Covid-19 hospitalizations may be substantial for those whose private insurers have allowed the cost-sharing waivers to expire. (To my readers in the UK and other countries with government healthcare — count yourselves lucky!) This study was peer-reviewed and published in the journal JAMA Network Open. You can read the full study here: <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785079">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2785079</a></p><p>2) Researchers studied 1,497 fully vaccinated healthcare workers in Israel, all of whom received the Pfizer vaccine. Of that group, 39 breakthrough infections (2.6%) were detected over a 14-week time period. Amongst those who experienced breakthrough infections, neutralizing antibody titers were found to be lower than those individuals in an uninfected control group. Most of the breakthrough cases were found to be mild (67%) or asymptomatic (33%), while 19% of those infected had persistent symptoms at least six weeks after being diagnosed. Their main symptoms were loss of smell, persistent cough, fatigue, weakness, dyspnea (shortness of breath), or myalgia (muscle aches). None of the people who experienced breakthrough infections needed to be hospitalized. The authors noted that the study’s sample included mostly young and healthy individuals, so the risk of severity from breakthrough infections could be different for other groups of people. The study was peer-reviewed and published in The New England Journal of Medicine. You can read the full text here: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2109072?query=recirc_mostViewed_railB_article">https://www.nejm.org/doi/full/10.1056/NEJMoa2109072?query=recirc_mostViewed_railB_article</a></p><p>3) A study published yesterday in the peer-reviewed journal Cancer Cell looked at the cellular responses to vaccines in people with multiple myeloma, a type of blood cancer (note — former US Secretary of State Colin Powell, who passed away yesterday due to complications from Covid-19 despite being fully vaccinated, had this blood cancer). The study involved just 44 patients, but showed that they produced fewer neutralizing antibodies to Covid-19. Additionally, their immune systems’ T-cell responses were quite weak. The researchers noted that their findings show the importance of using blood tests to monitor immune responses in patients with multiple myeloma after they have been vaccinated. They also stated, “With the current rapid spread of more transmissible viral variant (e.g., Delta variant), booster vaccination, continuing safety precautions, and passive antibody treatments should be considered in order to prevent morbidity and mortality from COVID-19 in MM patients with suboptimal vaccine responses.” You can view the full study here: <a href="https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00504-3">https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00504-3</a></p><p>4) Multiple news outlets such as <em>The Washington Post, The New York Times</em>, and <em>USA Today</em> are reporting that the US Food and Drug Administration (FDA) is set to give approval this week to the use of “mix and match” vaccines, meaning people could receive a booster dose of a vaccine that is different from the one they received during their first vaccination. This practice is already taking place in the UK and other nations such as Denmark and Germany. A study that is still undergoing peer review (important disclaimer) analyzed data from 458 individuals enrolled on a vaccine booster trial involving mixing and matching the Pfizer, Moderna, and Johnson &amp; Johnson vaccines. Results showed that all combinations of boosters increased neutralizing and binding antibody titers, suggesting that mixing and matching works. For those who received an initial dose of the J&amp;J vaccine, the Moderna booster was shown to result in the greatest increase (76-fold) in antibody levels, while a Pfizer booster offered a 35-fold increase, and a second dose of J&amp;J offered a fourfold increase. The authors concluded that “this preliminary report demonstrates that boosting with any of the three vaccines currently licensed or authorized for emergency use in the US will stimulate an anamnestic response in persons who previously received of the primary series of any of these vaccines.” You can read the full text pre-print of the study here: <a href="https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf">https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf</a></p><p>5) You may recall some US states (19 in total) offering lotteries in which people could win large sums of money if they got a Covid-19 vaccine. Researchers studied whether such statewide lotteries had any impact on vaccination rates. Findings revealed that the association between states announcing a vaccine lottery and the actual number of vaccinations administered was very small and statistically insignificant. The researchers concluded that lotteries may be less effective than incentives that pay people directly (e.g., giving someone $100 directly when they receive their vaccination). They also noted another possibility for the findings, that “drawings were not an informative vaccine promotional strategy and that more complete messaging on vaccination would have been far more effective.” This study was published in JAMA Health Forum and the full article can be read here: <a href="https://jamanetwork.com/journals/jama-health-forum/fullarticle/2785288">https://jamanetwork.com/journals/jama-health-forum/fullarticle/2785288</a></p><p>6) Now for a world update. The United States continues to see a drop in Covid-19 case numbers, with a 20% decrease over the past two weeks. The current seven-day average for daily new cases is 83,341. Hospitalizations have decreased 19% and the current average is 59,718 people in hospital. Deaths have decreased 11% and the current daily average is 1,631. Surges in new cases are being seen in states where temperatures are becoming much colder, such as Colorado, Vermont and Michigan. Of those eligible for a vaccine (age 12+), 67% of Americans are fully vaccinated and 77% have received one dose.<br> — The UK has experienced a 30% increase in daily new cases over the past two weeks. Yesterday there were 49,156 new cases recorded, which was the highest number in three months. There were 45 deaths yesterday and a total of 7,097 people in hospital. Only 14.2% of those aged 12–15 in England have been vaccinated, compared to 44.3% in Scotland. As a result, the UK will soon begin allowing this age group to receive their jabs at vaccination sites such as GP practices and pharmacies rather than only at schools. Just five days ago the number of students who were not in school for Covid-related reasons in England was 209,000.<br> — Elsewhere, Romania experienced its highest number of daily new cases yesterday with 18,800 and 574 deaths. Russia also experienced its highest number of deaths in one day with 1,105, as did Ukraine with 538. New Zealand had its highest number of cases ever with 94.<br> <br>Sources:<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br>UK numbers: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a><br>UK information: <a href="https://www.theguardian.com/politics/2021/oct/19/vaccine-centres-to-take-childrens-bookings-within-weeks-says-no-10">https://www.theguardian.com/politics/2021/oct/19/vaccine-centres-to-take-childrens-bookings-within-weeks-says-no-10</a><br>UK and world information: <a href="https://www.theguardian.com/world/live/2021/oct/19/covid-news-live-us-to-approve-mix-and-match-booster-shots-new-zealand-reports-record-daily-cases?page=with:block-616eadf98f08953dfa1a6c21#block-616eadf98f08953dfa1a6c21">https://www.theguardian.com/world/live/2021/oct/19/covid-news-live-us-to-approve-mix-and-match-booster-shots-new-zealand-reports-record-daily-cases?page=with:block-616eadf98f08953dfa1a6c21#block-616eadf98f08953dfa1a6c21</a></p><p>That’s all for this week! I’ll be back again next Tuesday with a new update.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6ffe7a2e3a2b" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-october-19-2021-6ffe7a2e3a2b">Weekly Covid-19 Update: Tuesday, October 19, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, October 12, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-october-12-2021-b9e15843cf1f?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/b9e15843cf1f</guid>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[covid-19-update]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 12 Oct 2021 19:50:18 GMT</pubDate>
            <atom:updated>2021-10-12T19:50:18.448Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. Here is the latest in Covid-related research. This week I’ve got information on Covid and mental health, the risk of heart inflammation after the Pfizer vaccine, the effectiveness of HEPA air filters to stop the spread of Covid, natural immunity versus vaccine immunity, the prevalence of Covid in secondary school students in the UK, and a world update.</p><p>1) Since Sunday was World Mental Health Day, I’ll start with a research item about mental health and Covid-19. A new peer-reviewed article published in The Lancet studied the prevalence of major depressive disorders and anxiety disorders in 204 countries and territories for the year 2020 during the Covid-19 pandemic. Findings showed that there were an estimated 76 million additional cases of anxiety globally than what would be expected in a non-pandemic year, and an additional 53.2 million cases of major depressive disorder. The locations hit hardest by Covid based on the number of daily new cases and decreased human mobility (due to lockdowns, etc.) had higher rates of these mental health issues. Females were significantly more affected by these issues than males and younger age groups were more affected than older age groups. The authors interpreted their findings in the following way: “This pandemic has created an increased urgency to strengthen mental health systems in most countries. Mitigation strategies could incorporate ways to promote mental wellbeing and target determinants of poor mental health and interventions to treat those with a mental disorder. Taking no action to address the burden of major depressive disorder and anxiety disorders should not be an option.” You can read the full study here: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02143-7/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02143-7/fulltext</a></p><p>2) Following up with another mental health-related study, researchers in France examined suicide attempts among children aged 15 years or younger during the 10 years before the Covid-19 pandemic as well as during the pandemic. The study involved 830 children who attempted suicide. The mean age was 13.5 years old and there was a 1:4 ratio of boys to girls. During the first lockdown period in France (March-April 2020), there was a 36% decrease in suicide attempts compared to the previous year. After that, though, the number of suicide attempts increased substantially, with a 116% increase in attempts during the months of September and October 2020 and a 299% increase in November and December 2020. Data available so far from 2021 continues to show increases in suicide attempts. Of these findings the authors stated, “our findings suggest that the COVID-19 pandemic is associated with profound changes in the dynamics of suicide attempts among children. There is a need for rapid deployment of evidence-based prevention and intervention strategies to address factors influencing suicide attempts among children during and likely after the pandemic.” The study was published in the peer-reviewed journal JAMA Network Open. You can read the full text here: <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784787">https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784787</a></p><p>3) Two large-scale studies concluded that the risk of heart inflammation after receiving the Pfizer vaccine is very low. Both studies were peer-reviewed and published in The New England Journal of Medicine and used data from Israel. The first study, a nationwide analysis of 5.1 million people, found 136 cases of myocarditis within one month of being vaccinated. Of those, 95% of the cases were classified as mild and one person died. The risk was slightly higher for men, with approximately 4 men out of 100,000 developing myocarditis. For women, the incidence was less than 1 in 100,000. Younger men aged 16–19 had a higher risk at 15 out of 100,000. The second study had very similar findings. Using data from 2.5 million people, the researchers found that the risk of myocarditis was 2 out of 100,000 after the Pfizer vaccine. They also found that younger men were at a higher risk than the general population. Most cases were mild or moderate in severity. You can read the full text of both studies at the following links:<br>Study 1: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2109730?query=featured_home">https://www.nejm.org/doi/full/10.1056/NEJMoa2109730?query=featured_home</a> <br>Study 2: <a href="https://www.nejm.org/doi/10.1056/NEJMoa2110737">https://www.nejm.org/doi/10.1056/NEJMoa2110737</a></p><p>4) As we all know very well by now, Covid is an airborne virus that primarily spreads through tiny droplets in the air. Researchers in the UK tested high-efficiency particulate air (HEPA) filters and ultra-violet (UV) light sterilization in a crowded hospital to determine how effective these were at clearing Covid particles from the air. They tested in a general Covid surge ward of the hospital as well as in a Covid ICU ward. Findings showed that airborne Covid was detected in the air in the surge ward on days when the air/UV filtration was not used, but was not detected during the days it was in use. Very few Covid particles were detected in the Covid ICU ward regardless of whether the air/UV filtration was used. The authors suggested this could be due to slower viral replication at later stages of the disease. The authors concluded, “These data demonstrate the feasibility of removing SARS-CoV-2 from the air of repurposed ‘surge’ wards and suggest that air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2.” The findings seem to reinforce the need to use HEPA filters to remove Covid-19 particles from the air in enclosed spaces. This study has not yet undergone peer review (important disclaimer!), but the pre-print can be read in full here: <a href="https://www.medrxiv.org/content/10.1101/2021.09.16.21263684v1">https://www.medrxiv.org/content/10.1101/2021.09.16.21263684v1</a></p><p>5) Researchers from King’s College London and the ZOE Covid Study released data on protection from Covid-19 infections for those who have been vaccinated and for those who previously recovered from Covid but have not been vaccinated (also known as “natural immunity”). Using data from May-June 2021 when the UK experienced a large wave of infections due to the Delta variant, the researchers found that a full course (2 jabs) of the Pfizer vaccine provided 87% protection against Covid. For those who were double-jabbed with Pfizer AND had previously recovered from Covid, protection was at 95%. For those who received the AstraZeneca vaccine the numbers were 71% and 90%, respectively. For those individuals who were never vaccinated but had recovered from Covid, protection via natural immunity was only 65%. A press release about the research stated that the finding “supports the call for everyone to get vaccinated even if they’ve already had COVID.” You can read the press release about the research here: <a href="https://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covid">https://covid.joinzoe.com/post/do-i-need-a-covid-vaccine-if-ive-had-covid</a></p><p>6) A report released by the Office of National Statistics (ONS) in the UK showed that 1 in 14 secondary school students (school year 7–11) were infected with Covid-19 last week. This was up from 1 in 20 the previous week. This age group had the sharpest rise in cases out of any age group in all of the UK, with those in the age 2 to school year 6 category ranking second. Those in secondary schools (age 12+) are now eligible for vaccines in the UK, but figures showed that only about 9% of those eligible in this age group had been vaccinated at the time of the report, which can be read in full here: <a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/8october2021">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/8october2021</a></p><p>7) Now for a world update. In the United States there has been a 24% decrease in new cases over the past two weeks. Yesterday there were 123,528 new cases and the daily average number of cases is down to 89,526. Hospitalizations have decreased 20% with approximately 67,000 people in hospital. Deaths have decreased 10% and the average number of daily deaths over the past week is 1,853. Case rates per 100,000 people remain highest in Alaska, Wyoming, North Dakota, Montana, and West Virginia. Of those eligible for a vaccine (age 12+), 66% of the US population has been fully vaccinated and 76% have had at least one dose.<br> — In the UK cases have increased 10% over the past two weeks. The current daily average number of new cases is 36,976. Today there were 38,520 new cases. A total of 7,003 people are currently hospitalized for Covid. Deaths have decreased 19% over the past two weeks and the current average daily deaths is 111. Among those eligible for a vaccine in the UK, 78.6% have received both doses. A scathing report published today by the House of Commons Health and Social Care and Science and Technology Committees stated that the UK government’s response to the pandemic “ranks as one of the most important public health failures the United Kingdom has ever experienced”.<br> — Elsewhere, Russia is testing a version of its vaccine (Sputnik V) in the form of nasal spray. Today Russia had its highest number of deaths ever since the pandemic began with 973. Thailand announced it will reopen its borders to vaccinated travelers starting in November. In Australia, yesterday marked the end of Sydney’s 107-day lockdown after the state of New South Wales reached a 70% vaccination rate for people aged 16 and older.<br>Sources:<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br>UK numbers: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a><br>UK vaccines: <a href="https://ourworldindata.org/covid-vaccinations?country=OWID_WRL">https://ourworldindata.org/covid-vaccinations?country=OWID_WRL</a><br>House of Commons report: <a href="https://committees.parliament.uk/publications/7496/documents/78687/default/">https://committees.parliament.uk/publications/7496/documents/78687/default/</a> <br>Russia and Thailand: <a href="https://www.theguardian.com/world/live/2021/oct/12/coronavirus-live-uk-covid-response-a-public-health-failure-inquiry-finds-thailand-set-to-welcome-back-tourists">https://www.theguardian.com/world/live/2021/oct/12/coronavirus-live-uk-covid-response-a-public-health-failure-inquiry-finds-thailand-set-to-welcome-back-tourists</a> <br>Sydney: <a href="https://www.bbc.co.uk/news/world-australia-58866464">https://www.bbc.co.uk/news/world-australia-58866464</a></p><p>That’s all for this week. I’ll be back next Tuesday with another update!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b9e15843cf1f" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-october-12-2021-b9e15843cf1f">Weekly Covid-19 Update: Tuesday, October 12, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, October 5, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-october-5-2021-a3707d2a0346?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/a3707d2a0346</guid>
            <category><![CDATA[coronavirus]]></category>
            <category><![CDATA[covid-update]]></category>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <category><![CDATA[covid19]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 05 Oct 2021 16:11:44 GMT</pubDate>
            <atom:updated>2021-10-05T16:16:06.720Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. Here is the latest in Covid-related research. This week I’ve got information on the effectiveness of mask requirements in schools, pregnancy and the Delta variant, antibodies in breast milk, smokers and Covid, autoantibodies, long Covid, Merck’s new Covid drug, and of course a world update.</p><ol><li>Two recent studies examined mask mandates in US schools. Not surprisingly, both studies found much lower rates of Covid-19 in schools with strict mask mandates. The first study assessed 520 US counties with clear mask policies (either a policy where everyone had to wear a mask or one in which no one had to wear a mask). Counties without school mask requirements experienced larger increases in pediatric Covid-19 cases than those with school mask requirements (34.85 cases per 100K people compared to 16.32 cases). The second study looked at 1,020 public schools in Arizona. Out of 191 Covid outbreaks during the study’s month and a half time period, 59% were in schools without mask requirements, compared to 8.4% in schools with early mask requirements. Those schools with no mask requirement were 3.5 times more likely to have outbreaks compared to schools with mask requirements. The study’s authors concluded, “Given the high transmissibility of the SARS-CoV-2 B.1.617.2 (Delta) variant, universal masking, in addition to vaccination of all eligible students, staff members, and faculty and implementation of other prevention measures, remains essential to COVID-19 prevention in K–12 settings.” Both studies were published in the CDC’s MMWR and can be read at the links below. <br>Study 1: <a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e3.htm?s_cid=mm7039e3_e&amp;ACSTrackingID=USCDC_921-DM66537&amp;ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20September%2024%2C%202021&amp;deliveryName=USCDC_921-DM66537">https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e3.htm?s_cid=mm7039e3_e&amp;ACSTrackingID=USCDC_921-DM66537&amp;ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20September%2024%2C%202021&amp;deliveryName=USCDC_921-DM66537</a> <br>Study 2: <a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e1.htm?s_cid=mm7039e1_e&amp;ACSTrackingID=USCDC_921-DM66537&amp;ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20September%2024%2C%202021&amp;deliveryName=USCDC_921-DM66537">https://www.cdc.gov/mmwr/volumes/70/wr/mm7039e1.htm?s_cid=mm7039e1_e&amp;ACSTrackingID=USCDC_921-DM66537&amp;ACSTrackingLabel=MMWR%20Early%20Release%20-%20Vol.%2070%2C%20September%2024%2C%202021&amp;deliveryName=USCDC_921-DM66537</a></li><li>A peer-reviewed study published in the American Journal of Obstetrics and Gynecology examined 1,515 pregnant women infected with the Delta variant of Covid-19 between May and September 2021. Of those, 82 women developed severe Covid, 81 of whom were unvaccinated. Of those, 10 required ventilation and two died. The rate of infection and proportion of severe or critical cases increased significantly with the Delta variant compared to previous variants. The authors concluded, “Increased morbidity was observed in pregnancy with COVID-19 during the recent surge associated with the Delta variant, particularly in an underserved pregnant population where vaccine acceptance is low.” They stressed the need for pregnant women to be vaccinated. You can read the full study here: <a href="https://www.sciencedirect.com/science/article/pii/S000293782101005X">https://www.sciencedirect.com/science/article/pii/S000293782101005X</a></li><li>Previous research found antibodies in the breast milk of women who had recovered from Covid, but scientists were unsure whether these antibodies would help protect babies against the virus. A new study took breast milk samples from 75 women who had recovered from Covid-19 and found IgA antibodies in 88% of the sample. These antibodies were shown to neutralize the virus, or block infection. The researchers found that these antibodies can remain in the milk for up to 10 months. A second study also examined the milk of women who were vaccinated and found coronavirus-specific IgG antibodies in 100% of the women who received the Moderna vaccine (71% had virus-specific IgA antibodies), 87% of those who received Pfizer (51% had IgA), and 38% of those who received J&amp;J (21% had IgA). Both of these studies are still undergoing peer review (important disclaimer!), but the pre-prints of each study can be found at the links below.<br>Study 1: <a href="https://www.medrxiv.org/content/10.1101/2021.03.16.21253731v1">https://www.medrxiv.org/content/10.1101/2021.03.16.21253731v1</a> <br>Study 2: <a href="https://www.medrxiv.org/content/10.1101/2021.07.19.21260794v1.full.pdf">https://www.medrxiv.org/content/10.1101/2021.07.19.21260794v1.full.pdf</a></li><li>Using data from 421,469 individuals in the UK, researchers found that people who smoke were 80% more likely to be hospitalized due to Covid-19 than non-smokers and also had a significantly higher risk of death. The researchers reported that their findings “support a causal effect of smoking on COVID-19 severity”, meaning that they were confident smoking causes more severe cases of Covid-19. The study was peer-reviewed and published in the BMJ journal Thorax. You can read the full text here: <a href="https://thorax.bmj.com/content/early/2021/09/12/thoraxjnl-2021-217080">https://thorax.bmj.com/content/early/2021/09/12/thoraxjnl-2021-217080</a></li><li>I’ve written about autoantibodies being discovered in the blood of patients with severe Covid-19 in the past. A new study involving 147 patients with severe Covid found these autoantibodies in approximately 50% of the patients. The researchers took blood samples for the patients at different time periods, including the day they were first hospitalized. Findings showed that approximately 20% of patients developed new autoantibodies within a week of hospitalization. In a press release about the study, which was published in the peer-reviewed journal Nature Communications, the lead researcher Dr Paul Utz of Stanford University said that the levels of autoantibodies seen in these patients were similar to those found in diagnosed autoimmune diseases and it is possible these patients could go on to develop autoimmune diseases in the future, but long-term research is necessary to determine this. The study concluded, “While the COVID-19 pandemic is leaving a wake of destruction as it progresses, it also provides an unprecedented opportunity to understand how exposure to a new virus could potentially break tolerance to self, potentially giving rise to autoimmunity and other chronic, immune-mediated, diseases.” You can read the full study here: <a href="https://www.nature.com/articles/s41467-021-25509-3">https://www.nature.com/articles/s41467–021–25509–3</a><br>And the press release here: <a href="https://med.stanford.edu/news/all-news/2021/09/covid-19-autoantibodies.html">https://med.stanford.edu/news/all-news/2021/09/covid-19-autoantibodies.html</a></li><li>One thing I often wrote in the early days of the pandemic and the early days of these research updates was something along the lines of, “There is still so much we don’t know about the long-term effects of this virus.” Indeed, we are still learning. New research on long Covid showed that out of 273,618 Covid survivors, 36.55% had at least one symptom of long Covid between 3–6 months after testing positive. Out of all Covid survivors, anxiety and/or depression was the most common symptom experienced during the 3–6 month post-Covid time period (15%), followed by abnormal breathing (8%), abdominal symptoms (8%), other pain (7%), chest/throat pain (6%), fatigue (6%), and headache (5%). The researchers found that the risk of long Covid was higher in patients who had more severe cases, it was slightly higher among females, and there were no differences based on race. The study was peer-reviewed and published in the journal PLOS Medicine and can be read in full here: <a href="https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003773">https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003773</a></li><li>In additional long Covid news, new research in the UK showed that 12.3% of English secondary school students (equivalent to junior high and high school for my US readers) and 35.7% of school staff members reported ongoing Covid symptoms at least four weeks after initially testing positive. The most common symptom was weakness/tiredness for both staff (59.6%) and students (46.3%), followed by shortness of breath for staff (41.8%) and loss of smell for students (37.0%). Of those who experienced long Covid symptoms, 15.5% of the staff members and 9.4% of the students said their ability to carry out day-to-day activities was significantly reduced. The data were reported by the Office of National Statistics and the full report can be read here: <a href="https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyenglandprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectioninschoolpupilsandstaff/july2021">https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyenglandprevalenceofongoingsymptomsfollowingcoronaviruscovid19infectioninschoolpupilsandstaff/july2021</a></li><li>Since the start of the pandemic there have been questions about how the virus originated. While some believed it could have been man-made in a laboratory, recent research found three coronaviruses in bats living in caves in Laos that add “substantial weight to existing evidence that the virus was not engineered” according to an article from Science. The three viruses are the closest relatives to SARS-CoV-2 (Covid-19) that have been found to date. One of the newly discovered coronaviruses is 96.8% identical in its genetic sequence to Covid, while another one is 96.2% identical. It is very important to note that the study is currently under peer review at the journal Nature Portfolio, so it has not yet been accepted by a peer-reviewed journal. You can read the full text of the pre-print here: <a href="https://www.researchsquare.com/article/rs-871965/v1">https://www.researchsquare.com/article/rs-871965/v1</a></li><li>Pharmaceutical company Merck announced that it has developed an experimental antiviral pill that could halve the chances of death or hospitalization from Covid-19. The company’s results involved data from 775 Covid patients who were not hospitalized. They all joined the study within five days of developing symptoms and all had at least one risk factor for severe Covid. This drug is “the first oral antiviral that has proved to be effective against SARS-CoV-2” according to an article from Science. Merck plans to apply to the US Food and Drug Administration for emergency use authorization. In previous research the drug was shown not to be effective in patients who were already hospitalized. You can read an article about the drug here: <a href="https://www.science.org/content/article/unquestionably-game-changer-antiviral-pill-cuts-covid-19-hospitalization-risk">https://www.science.org/content/article/unquestionably-game-changer-antiviral-pill-cuts-covid-19-hospitalization-risk</a></li><li>Now for your world update. In the US, the daily number of new cases has decreased 24% over the last two weeks. The current average number of new cases per day is 103,785. Hospitalizations have decreased 20% over the past two weeks and deaths have decreased 12%. Of those who are eligible for a vaccine (age 12+), 66% of people in the US are fully vaccinated. In the 65+ age group that number is 84%. State trends show that Alaska, Montana, North Dakota, West Virginia, and Wyoming have the most cases per capita, while Connecticut, California, Louisiana, Hawaii, and New Jersey have the fewest cases per capita.<br> — In the UK the number of daily new cases has increased 12% over the past two weeks. The current average number of new daily cases is 33,317. Deaths have decreased by 21% over the past two weeks. In England, 90% of people age 16+ have received a first vaccine dose and 82% have been fully vaccinated. Currently there are over 100,000 children in England who are out of school with confirmed Covid cases. <br> — Elsewhere, Australia has announced it will open its borders when 80% of the population aged 16 and older has been vaccinated, but the priority will be on bringing skilled migrants and students into the country. The Prime Minister indicated that international travel visitors would likely not be welcomed into Australia until 2022. Meanwhile, New Zealand announced it will abandon its zero-Covid strategy and instead learn to live with the virus. Only 49% of the NZ population is fully vaccinated, while 79% have received one dose. Both Portugal and Norway announced today that they would begin giving booster vaccines to everyone over the age of 65. Portugal currently has the world’s highest vaccination rate with 85% of its population fully vaccinated.<br>Sources<br>US data: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html">https://www.nytimes.com/interactive/2021/us/covid-cases.html</a> <br>UK data: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a> <br>England vaccinations: <a href="https://www.bbc.co.uk/news/health-55274833">https://www.bbc.co.uk/news/health-55274833</a> <br>Australia travel: <a href="https://abcnews.go.com/Health/wireStory/australia-international-tourists-2022-80406703">https://abcnews.go.com/Health/wireStory/australia-international-tourists-2022-80406703</a> <br>New Zealand: <a href="https://edition.cnn.com/2021/10/05/asia/new-zealand-ardern-covid-zero-intl-hnk/index.html">https://edition.cnn.com/2021/10/05/asia/new-zealand-ardern-covid-zero-intl-hnk/index.html</a> <br>Other world updates: <a href="https://www.theguardian.com/world/live/2021/oct/05/coronavirus-live-news-california-deploys-national-guard-pfizer-jab-highly-effective-against-hospitalisations?page=with:block-615c41138f084fb3bf98d742#block-615c41138f084fb3bf98d742">https://www.theguardian.com/world/live/2021/oct/05/coronavirus-live-news-california-deploys-national-guard-pfizer-jab-highly-effective-against-hospitalisations?page=with:block-615c41138f084fb3bf98d742#block-615c41138f084fb3bf98d742</a></li></ol><p>That’s all for this week. If you made it this far, thanks for sticking with me. I realize this was a long update!</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=a3707d2a0346" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-october-5-2021-a3707d2a0346">Weekly Covid-19 Update: Tuesday, October 5, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Weekly Covid-19 Update: Tuesday, September 21, 2021]]></title>
            <link>https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-september-21-2021-af1c3c32054e?source=rss----7d3227ef66e6---4</link>
            <guid isPermaLink="false">https://medium.com/p/af1c3c32054e</guid>
            <category><![CDATA[covid-19-research]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[coronavirus-research]]></category>
            <category><![CDATA[covid-19-update]]></category>
            <category><![CDATA[coronavirus]]></category>
            <dc:creator><![CDATA[Andrea Geurin]]></dc:creator>
            <pubDate>Tue, 21 Sep 2021 15:52:43 GMT</pubDate>
            <atom:updated>2021-09-21T15:57:22.379Z</atom:updated>
            <content:encoded><![CDATA[<p>Happy Tuesday, everyone. Here is the latest in Covid-19 research. This week I’ve got information on the effectiveness of pre-flight Covid-19 tests in minimizing the spread of the virus, Pfizer booster dose results in the 60+ age group, school measures for students who are close contacts, groups at greater risk of long Covid, Pfizer’s announcement that its vaccine is safe and effective in the 5–11 age group, J&amp;J’s booster dose trial results, and as always, a world update.</p><p>1) Many nations and/or airlines require proof of a negative pre-flight Covid-19 test. How well do these actually work in weeding out infected individuals? Researchers tracked passengers on 129 international flights from the United States to Italy from December 2020 to April 2021. All passengers were required to show proof of a negative test taken within 72 hours, then they were re-tested at the airport using a rapid antigen test. If that test came back positive they were tested again using a rapid molecular test. Out of 9,853 passengers, only four (0.04%) tested positive at the airport and were not allowed to travel. The researchers also found that out of the 9,849 passengers who passed their pre-travel tests and were allowed to fly, only one (0.01%) person tested positive upon arrival in Italy, where all passengers were once again tested. The authors concluded, “These data suggest that even at this higher level of active community infection, a single molecular test performed within 72 hours of departure can decrease the rate of active infection on board a commercial aircraft to a level that is several orders of magnitude below active community infection rates. The addition of other interventions, including universal masking at the airport and onboard aircraft, increase in frequency of air exchanges and enhanced cleaning, physical distancing during deplaning activities, increasing vaccination rates among travelers and exclusion of symptomatic individuals, further enhances safety.” The study was peer-reviewed and published in the Mayo Clinic Proceedings You can read the full study here: <a href="https://www.mayoclinicproceedings.org/article/S0025-6196(21)00644-3/fulltext#relatedArticles">https://www.mayoclinicproceedings.org/article/S0025-6196(21)00644-3/fulltext#relatedArticles</a></p><p>2) Booster doses of the Pfizer vaccine were tested on over 1.1 million people aged 60 and over in Israel who had already been fully vaccinated at least five months earlier. The study found that, “At least 12 days after the booster dose, the rate of confirmed infection was lower in the booster group than in the nonbooster group by a factor of 11.3; the rate of severe illness was lower by a factor of 19.5.” The authors stated that it is critical to understand the protection gained by a booster dose to assist in making public health policies and that their findings “give clear indications of the effectiveness of a booster dose even against the currently dominant delta variant.” The study was peer-reviewed and published in The New England Journal of Medicine. You can read the full text here: <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2114255">https://www.nejm.org/doi/full/10.1056/NEJMoa2114255</a></p><p>3) Schools often ask close contacts of those infected with Covid-19 to self-isolate at home, which results in students missing valuable educational opportunities. A study conducted in the UK between March and May 2021 randomly assigned 99 schools to mandate 10 days of self-isolation for any close contacts of a confirmed Covid-19 case. They also randomly assigned 102 schools to have close contacts stay in school but test daily with a lateral flow device (rapid test) for seven days after exposure. Findings showed that in the schools that implemented self-isolation there were 657 symptomatic PCR-confirmed infections in close contacts over the time period of the study, whereas the lateral flow testing group had 740 confirmed cases. They found no statistically significant differences between the two groups and concluded, “Daily contact testing is a safe alternative to home isolation in school-based contacts and should be considered an alternative to routine isolation of close contacts following school-based exposures.” The study was peer-reviewed and published in The Lancet. You can read the full study here: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01908-5/fulltext#seccestitle150">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01908-5/fulltext#seccestitle150</a></p><p>4) A study involving 28,594 recovered Covid-19 patients in Long Beach, California revealed that one-third of those individuals experienced long Covid two months after initially testing positive for the virus. Significantly higher rates of long Covid were found in individuals over 40 years old, females, people who were Black, and people who reported having at least one pre-existing condition. The researchers did not collect data on specific pre-existing conditions, therefore I cannot tell you which ones might indicate higher risk of long Covid. This study used data gathered from April to December 2020 before vaccines were available, therefore these individuals were unvaccinated. The researchers noted that “identification of populations disproportionately affected by COVID-19 and long COVID can help guide efforts to prioritize prevention and treatment.” The study was published in the CDC’s Morbidity and Mortality Weekly Report and can be read in full here: <a href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a2.htm?s_cid=mm7037a2_w">https://www.cdc.gov/mmwr/volumes/70/wr/mm7037a2.htm?s_cid=mm7037a2_w</a></p><p>5) Yesterday Pfizer announced its vaccine was safe and effective in the 5–11 age group. The statement from Pfizer and their partner, BioNTech, did not include specific data from the trial, nor have the results been peer reviewed or published in an academic journal. Their statement said that they used a smaller dose than in the 12+ age groups, and a total of 2,268 children were enrolled in the Phase 2/3 study. They reported a slightly stronger immune response in the 5–11 age group after their second dose compared to a control group comprised of individuals ages 16–25 who received the standard adult dose of the vaccine. The statement also said that the side effects experienced in the 5–11 age group were “generally comparable to those observed in participants 16 to 25 years of age.” The companies plan to submit data to the US Food and Drug Administration (FDA) for emergency use authorization by the end of this month, as well as to the European Medicines Agency (EMA) and other regulators. An article in the New York Times noted that children now account for more than 1 in 5 new cases of Covid-19 in the US, and over 30,000 children were hospitalized due to Covid in the month of August in the US, underscoring the need for a safe vaccine for children. <br>You can read the Pfizer/BioNTech press release here: <a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results</a><br>And a New York Times article about the announcement here: <a href="https://www.nytimes.com/2021/09/20/health/covid-children-vaccine-pfizer.html">https://www.nytimes.com/2021/09/20/health/covid-children-vaccine-pfizer.html</a></p><p>6) Today Johnson &amp; Johnson released a statement saying that a booster dose of its vaccine (given two months after the initial dose) was shown to provide stronger protection against Covid-19. The statement said that two doses of its vaccine resulted in 94% efficacy against symptomatic Covid-19 (compared to just 74% with a single dose of the vaccine) and 100% efficacy against severe Covid based on trial data. Additionally, antibody levels rose four to six times higher after the second shot than after a single dose of the vaccine. J&amp;J submitted their data to the FDA to seek authorization for its booster dose. You can read the company’s full statement here: <a href="https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s">https://www.jnj.com/johnson-johnson-announces-real-world-evidence-and-phase-3-data-confirming-strong-and-long-lasting-protection-of-single-shot-covid-19-vaccine-in-the-u-s</a></p><p>7) Now for your world update. The US reported 207,974 new cases of Covid-19 yesterday. The seven-day average for daily new cases is 137,295, which is a 4% increase over the past two weeks. Hospitalizations are down 8% over the last two weeks, with 93,501 people hospitalized. Deaths have increased 51% over the past two weeks and the average daily number of deaths is 2,087. As of yesterday, more Americans have died from Covid-19 (676,191) than those who died of influenza during the 1918 pandemic (approximately 675,000). Looking at the number of new cases per 100,000 people, Alaska is currently doing the worst per capita with 114 out of 100K, followed by West Virginia (101), Kentucky (94), Wyoming (91), and Montana (86). In terms of vaccinations, 66% of Americans age 18+ have been fully vaccinated. When looking at all people eligible for a vaccine (age 12+), 64% have been fully vaccinated.<br> — The UK recorded 35,702 new cases yesterday. Over the past two weeks there has been a 20% drop in the number of new daily cases and the current daily average is 29,841. Deaths have increased 26% and the daily average over the past two weeks is 142. There are currently 7,847 Covid patients in hospital in the UK. Today booster jabs began for those over the age of 50 and first doses of the vaccine began for those in the 12–15 age group. Figures from the UK’s Department of Education showed that the recent reopening of schools in England led to a surge in Covid cases in children, with 59,000 students absent from school with confirmed Covid cases on the 16th of September and 45,000 others absent with suspected cases.<br> — Elsewhere, Singapore is considering making vaccines mandatory as their vaccination rate has flattened at 82% and amid surging case numbers due to the Delta variant. In the Netherlands, the government said it will require ‘vaccine passes’ for restaurant customers to use the toilet. A 20-year-old German student who worked at a gas station in the town of Idar-Oberstein was shot and killed after refusing to serve a customer who was not wearing a mask (masks are mandatory in shops in Germany). In the Chinese city of Harbin, one confirmed Covid-19 case prompted the city of 10 million to shut down nearly all indoor venues in line with China’s “zero tolerance” approach to Covid.<br>Sources:<br>US numbers: <a href="https://www.nytimes.com/interactive/2021/us/covid-cases.html?name=styln-coronavirus&amp;region=TOP_BANNER&amp;block=storyline_menu_recirc&amp;action=click&amp;pgtype=LegacyCollection&amp;variant=1_Show&amp;is_new=false">https://www.nytimes.com/interactive/2021/us/covid-cases.html?name=styln-coronavirus&amp;region=TOP_BANNER&amp;block=storyline_menu_recirc&amp;action=click&amp;pgtype=LegacyCollection&amp;variant=1_Show&amp;is_new=false</a><br>UK numbers: <a href="https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html">https://www.nytimes.com/interactive/2021/world/united-kingdom-covid-cases.html</a> <br>UK school data: <a href="https://www.theguardian.com/world/live/2021/sep/21/coronavirus-live-news-uk-welcomes-end-of-us-travel-ban-american-covid-death-toll-passes-1918-19-flu-pandemic?page=with:block-6149c33e8f086e40d2e8ccb9#block-6149c33e8f086e40d2e8ccb9">https://www.theguardian.com/world/live/2021/sep/21/coronavirus-live-news-uk-welcomes-end-of-us-travel-ban-american-covid-death-toll-passes-1918-19-flu-pandemic?page=with:block-6149c33e8f086e40d2e8ccb9#block-6149c33e8f086e40d2e8ccb9</a> <br>Other updates: <a href="https://www.theguardian.com/world/live/2021/sep/21/coronavirus-live-news-uk-welcomes-end-of-us-travel-ban-american-covid-death-toll-passes-1918-19-flu-pandemic?page=with:block-61497d5b8f0887fe13f5884e#liveblog-navigation">https://www.theguardian.com/world/live/2021/sep/21/coronavirus-live-news-uk-welcomes-end-of-us-travel-ban-american-covid-death-toll-passes-1918-19-flu-pandemic?page=with:block-61497d5b8f0887fe13f5884e#liveblog-navigation</a> <br>German killing: <a href="https://www.nytimes.com/2021/09/21/world/germany-coronovirus-shooting-covid.html">https://www.nytimes.com/2021/09/21/world/germany-coronovirus-shooting-covid.html</a> <br>Chinese shutdown: <a href="https://www.nytimes.com/live/2021/09/21/world/covid-delta-variant-vaccine/one-covid-case-prompts-closures-across-a-chinese-city-of-10-million">https://www.nytimes.com/live/2021/09/21/world/covid-delta-variant-vaccine/one-covid-case-prompts-closures-across-a-chinese-city-of-10-million</a></p><p>That’s all for this week. Thank you if you took the time to read this, and please feel free to share it with others.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=af1c3c32054e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/weekly-coronavirus-update/weekly-covid-19-update-tuesday-september-21-2021-af1c3c32054e">Weekly Covid-19 Update: Tuesday, September 21, 2021</a> was originally published in <a href="https://medium.com/weekly-coronavirus-update">Weekly Coronavirus Update</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>